NRx Pharmaceuticals, Inc. – NASDAQ:NRXPW

Founder-led company

NRx Pharmaceuticals stock price today

$0.07
Financial Health
0
1
2
3
4
5
6
7
8
9

NRx Pharmaceuticals stock price monthly change

-3.30%
month

NRx Pharmaceuticals stock price quarterly change

-3.30%
quarter

NRx Pharmaceuticals stock price yearly change

-53.87%
year

NRx Pharmaceuticals key metrics

Market Cap
 20.65M
Enterprise value
 N/A
P/E
 -0.02
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 1.33
PEG ratio
 N/A
EPS
 -0.98
Revenue
 N/A
EBITDA
 -24.13M
Income
 -25.63M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

NRx Pharmaceuticals stock price history

NRx Pharmaceuticals stock forecast

NRx Pharmaceuticals financial statements

Profit Margin

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW): Profit margin
Jun 2023 0 -8.71M
Sep 2023 0 -6.06M
Dec 2023 8K -4.33M -54150%
Mar 2024 0 -6.52M
NRXPW income statement history

Debt to Assets

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW): Debt to assets
Jun 2023 19809000 22.61M 114.18%
Sep 2023 13110000 19.32M 147.42%
Dec 2023 7315000 19.04M 260.4%
Mar 2024 3788000 18.85M 497.81%
NRXPW balance sheet history

Cash Flow

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW): Cash Flow
Jun 2023 -7.81M 2K 6.27M
Sep 2023 -4.56M -2K -1.50M
Dec 2023 -3.19M 1K -1.11M
Mar 2024 -3.67M 0 395K
NRXPW cash flow history

NRx Pharmaceuticals other data

NRx Pharmaceuticals
Hedge Funds Holdings Q1 2023

0.03% +0.01%
of NRXPW is owned by hedge funds
2 +1
hedge funds hold NRXPW stock
20.48K +3.35K
shares is hold by hedge funds
NRXPW hedge funds holdings changes

NRx Pharmaceuticals
Insider Trading

NRx Pharmaceuticals, Inc. (NASDAQ:NRXPW): Insider trades (number of shares)
Period Buy Sel
Jun 2022 100000 445712
Jul 2022 0 784063
Nov 2022 235275 238108
Dec 2022 80000 400000
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
WILLARD STEPHEN H director, officer: CHIEF EXECUT..
 Common Stock, par value $0.001 per share 50,000 $1.17 $58,500
Purchase
VAN VOORHEES SETH officer: CHIEF FINANCIAL OFFICER
 Common Stock, par value $0.001 per share 30,000 $1.1 $33,000
Sale
JAVITT JONATHAN C director, 10 perc.. Common Stock, par value $0.001 per share 400,000 $1 $400,000
Sale
JAVITT JONATHAN C director, 10 perc.. Common Stock, par value $0.001 per share 400,000 $1 $400,000
Sale
JAVITT DANIEL C. 10 percent owner
 common stock 8,441 $1.51 $12,704
Sale
JAVITT DANIEL C. 10 percent owner
 common stock 13,730 $1.5 $20,650
Purchase
FLYNN PATRICK JOHN director
 Common Stock, par value $0.001 per share 2,500 $1.24 $3,100
Purchase
FLYNN PATRICK JOHN director
 Common Stock, par value $0.001 per share 2,500 $1.25 $3,125
Purchase
FLYNN PATRICK JOHN director
 Common Stock, par value $0.001 per share 1,750 $1.25 $2,188
Purchase
VAN VOORHEES SETH officer: CHIEF FINANCIAL OFFICER
 Common Stock, par value $0.001 per share 8,716 $1.12 $9,762
NRXPW insider trading transactions

NRx Pharmaceuticals
Executives

Insider Compensation
Dr. Jonathan C. Javitt M.D., M.P.H. (1957) Co-Founder, Chairman & Chief Executive Officer $471,050
Mr. Robert Besthof M.I.M. (1966) Head of Operations & Chief Commercial Officer and Patient Officer
 $214,380

Frequently Asked Questions (FAQ)

  • What's the price of NRx Pharmaceuticals stock today?

    One share of NRx Pharmaceuticals stock can currently be purchased for approximately $0.07.

  • When is NRx Pharmaceuticals's next earnings date?

    Unfortunately, NRx Pharmaceuticals's (NRXPW) next earnings date is currently unknown.

  • Does NRx Pharmaceuticals pay dividends?

    No, NRx Pharmaceuticals does not pay dividends.

  • How much money does NRx Pharmaceuticals make?

    NRx Pharmaceuticals has a market capitalization of 20.65M.

  • What is NRx Pharmaceuticals's stock symbol?

    NRx Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "NRXPW".

  • What is NRx Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of NRx Pharmaceuticals?

    Shares of NRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are NRx Pharmaceuticals's key executives?

    NRx Pharmaceuticals's management team includes the following people:

    • Dr. Jonathan C. Javitt M.D., M.P.H. Co-Founder, Chairman & Chief Executive Officer(age: 68, pay: $471,050)
    • Mr. Robert Besthof M.I.M. Head of Operations & Chief Commercial Officer and Patient Officer(age: 59, pay: $214,380)

  • Is NRx Pharmaceuticals founder-led company?

    Yes, NRx Pharmaceuticals is a company led by its founder Dr. Jonathan C. Javitt M.D., M.P.H..

  • When NRx Pharmaceuticals went public?

    NRx Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 1 Dec 2017.

  • What is NRx Pharmaceuticals's official website?

    The official website for NRx Pharmaceuticals is nrxpharma.com.

  • Where are NRx Pharmaceuticals's headquarters?

    NRx Pharmaceuticals is headquartered at 1201 Orange Street, Wilmington, DE.

  • How can i contact NRx Pharmaceuticals?

    NRx Pharmaceuticals's mailing address is 1201 Orange Street, Wilmington, DE and company can be reached via phone at +48 42546134.

NRx Pharmaceuticals company profile:

NRx Pharmaceuticals, Inc.

nrxpharma.com
Exchange:

NASDAQ

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

+48 42546134
1201 Orange Street
Wilmington, DE 19801

CIK: 0001719406
ISIN: US6294441182
CUSIP: 629444118